Skip to main content

Table 3 Regression analyses assessing predictive factors of clinical atherosclerosis

From: Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study

Clinical variables

OR

95%CI

p

Univariate analyses

 Age

1.01

0.99–1.03

0.30

 Male gender

1.14

0.63–2.08

0.65

 RF

1.33

0.77–2.32

0.31

 ACPA

0.73

0.45–1.28

0.20

 Disease duration

0.99

0.95–1.02

0.58

 Extra-articular features

1.67

0.94–2.93

0.08

 Radiographic damage

089

0.55–1.43

0.63

 Joint surgery

0.82

0.38–1.76

0.61

 Maintenance of remission

0.55

0.34–0.91

0.20

 CRP

1.02

0.99–1.05

0.14

 BMI

1.05

0.99–1.08

0.11

 HBP

10.69

5.06–22.59

< 0.0001

 High cholesterol

2.47

0.56–5.9

0.18

 Smoking habit

0.80

0.47–1.35

0.40

 MetS

6.27

3.79–10.37

< 0.0001

 T2D

2.64

1.48–4.71

0.001

 ASA

1.11

0.78–2.01

0.85

 CCS

1.44

0.81

2.56

 CCSs low dosage

1.91

0.89–3.46

0.09

 MTX

1.31

0.64–2.72

0.45

 HCQ

0.61

0.34–1.08

0.09

 LEF

0.51

0.25–1.07

0.07

 SSZ

0.53

0.23–1.24

0.14

 Biologic DMARDs

0.67

0.29–1.36

0.35

 TNFi

0.55

0.32–1.01

0.07

 Non-TNFi

0.59

0.31–1.02

0.09

Multivariate analysis

 Age

1.01

0.99–1.05

0.44

 Male gender

0.62

0.22–1.73

0.36

 HBP

1.85

0.69–4.91

0.21

 T2D

6.21

2.19–17.71

0.001

 Remission

0.20

0.09–0.95

0.041

  1. Italicised values are statistically significant (p < 0.05)
  2. Abbreviations: RF rheumatoid factor, ACPA Anti-citrullinated protein antibodies, CRP mean values of C reactive protein during the follow-up, BMI mean body mass index during the follow-up, MetS metabolic syndrome, HBP high blood pressure, T2D type 2 diabetes, ASA acetylsalicylic acid, aspirin, CCSs corticosteroids, MTX methotrexate, HCQ hydroxychloroquine, SSZ sulfasalazine, LEF leflunomide, TNFi tumour necrosis factor inhibitor